EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-SA 4.0

Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review

Remya Rajan, Devika Nandakumar

Indian Journal of Endocrinology and Metabolism · 2025-07 · 29 (4) · 408-413

DOI: 10.4103/ijem.ijem_47_25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Endocrinology and Metabolism, online erschienen am 26.08.2025. Verfasst von Remya Rajan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, Christian Medical College Vellore, Vellore, Tamil Nadu, India. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy by enhancing T-cell-mediated tumour eradication. However, their use is associated with immune-related adverse events, with endocrinopathies being the most common. Thyroid dysfunction, hypophysitis, primary adrenal insufficiency (PAI), and insulin-dependent diabetes mellitus are well-documented complications. Thyroid dysfunction typically follows a biphasic course, with transient thyrotoxicosis progressing to hypothyroidism. Hypophysitis primarily affects the anterior pituitary, often leading to isolated adrenocorticotropic hormone deficiency. ICI-induced diabetes mellitus results from autoimmune β-cell destruction, frequently presenting as diabetic ketoacidosis. Primary adrenal insufficiency is rare but requires prompt recognition. Despite these endocrine toxicities, the benefits of ICIs outweigh their risks, and treatment is usually continued with appropriate hormone replacement. Early recognition and management of these endocrinopathies are crucial for optimising patient outcomes. This review summarises the incidence, pathophysiology, diagnosis, and management of ICI-associated endocrine disorders, providing essential insights for oncologists and endocrinologists.

Schlagwörter

Stichwörter der Autor:innen

Endocrinopathyhypophysitisimmune checkpoint inhibitorthyroiditis

Autor:innen und Institutionen

  • Department of Endocrinology, Diabetes and Metabolism, Christian Medical College Vellore, Vellore, Tamil Nadu, India.

Zitieren

APA

Rajan, R., & Nandakumar, D. (2025). Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review. Indian Journal of Endocrinology and Metabolism, 29(4), 408-413. https://doi.org/10.4103/ijem.ijem_47_25

Vancouver

Rajan R, Nandakumar D. Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review. Indian Journal of Endocrinology and Metabolism. 2025;29(4):408-413. doi:10.4103/ijem.ijem_47_25

BibTeX
@article{Rajan2025,
  author = {Rajan, Remya and Nandakumar, Devika},
  title = {Endocrine Adverse Events of Immune Checkpoint Inhibitors: A Comprehensive Review},
  journal = {Indian Journal of Endocrinology and Metabolism},
  year = {2025},
  volume = {29},
  number = {4},
  pages = {408--413},
  doi = {10.4103/ijem.ijem_47_25}
}
Kostenlos starten →